Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial of Radiofrequency Ablation for the Treatment of Paroxysmal Atrial Fibrillation Using the Bard High Density Mesh Ablation System (MAGELLAN)

NCT00741611 is registered in ClinicalTrials.gov with C. R. Bard as lead sponsor.

NCT NCT00741611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00741611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial of Radiofrequency Ablation for the Treatment of Paroxysmal Atrial Fibrillation Using the Bard High Density Mesh Ablation System (MAGELLAN)
Lead sponsor
C. R. Bard
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2008
Completion date
November 30, 2009
Enrollment
44 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal atrial fibrillation